BULDINI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4278
EU - Europa 280
AS - Asia 228
SA - Sud America 9
OC - Oceania 3
AF - Africa 2
Totale 4800
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4264
CN - Cina 191
FI - Finlandia 64
IT - Italia 57
SE - Svezia 45
DE - Germania 39
VN - Vietnam 24
UA - Ucraina 23
GB - Regno Unito 20
CA - Canada 14
IN - India 13
IE - Irlanda 11
CO - Colombia 8
AT - Austria 4
NL - Olanda 4
RU - Federazione Russa 4
AU - Australia 2
BG - Bulgaria 2
FR - Francia 2
ZA - Sudafrica 2
BE - Belgio 1
BR - Brasile 1
DK - Danimarca 1
ES - Italia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RO - Romania 1
Totale 4800
Salva come PNG Salva come JPEG
Città #
Fairfield 846
Woodbridge 494
Chandler 386
Ann Arbor 360
Houston 348
Cambridge 308
Ashburn 288
Seattle 255
Wilmington 215
San Diego 117
Jacksonville 92
Princeton 84
Des Moines 69
Medford 64
Beijing 47
Guangzhou 35
Roxbury 31
Padova 29
Helsinki 28
Boardman 27
Dong Ket 24
Nanjing 24
Hebei 17
North York 14
Dearborn 12
Dublin 11
Nanchang 11
Chicago 10
London 10
Redmond 10
Falls Church 9
Shenyang 9
Santa Cruz 8
Jiaxing 7
Redwood City 6
Tianjin 6
Bandra 5
Changsha 5
Jinan 5
Norwalk 5
Haikou 4
Kharkiv 4
Kunming 4
Detroit 3
Vienna 3
Bordighera 2
Borås 2
Hangzhou 2
Leawood 2
Legnaro 2
Rockville 2
Selvazzano Dentro 2
Sofia 2
Tettnang 2
Vergato 2
Waverly 2
Agrigento 1
Bengaluru 1
Bresso 1
Brussels 1
Catania 1
Cheyenne 1
Copenhagen 1
Enschede 1
Frankfurt am Main 1
Fuzhou 1
Geislingen an der Steige 1
Groningen 1
Lanzhou 1
Montecchio Precalcino 1
Napoli 1
New Delhi 1
New York 1
Nürnberg 1
Orange 1
Pasadena 1
Phoenix 1
Pinehaven 1
Qingdao 1
Samara 1
San Francisco 1
Shanghai 1
Strathfield 1
São Paulo 1
Trieste 1
Valencia 1
Warsaw 1
Zhengzhou 1
Totale 4403
Salva come PNG Salva come JPEG
Nome #
Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group 143
Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. 124
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. 109
Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow 106
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. 100
Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients 99
IDENTIFICATION OF IMMUNOPHENOTYPIC SIGNATURES BY CLUSTERING ANALYSIS IN PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 98
Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia 98
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-Lineage acute lymphoblastic leukemia. 96
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. 96
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 91
Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience 91
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. 90
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols 89
Health technology assessment–based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification 86
null 84
A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia 82
Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia 81
Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children 79
CD371 cell surface expression: A unique feature of DUX4-rearranged acute lymphoblastic leukemia 78
Trisomy 7 and deletion of the 9p21 locus as novel acquired abnormalities in a case of pediatric biphenotypic acute leukemia. 77
Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping. 77
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 77
MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study 77
Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols 77
International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia 75
Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. 74
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 74
Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing 74
AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia 73
Immunophenotype segnature as a tool to define prognostic subgroups in childhood acute myeloid leucemia. 72
Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients 71
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 71
Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation 70
The genetic basis and cell of origin of mixed phenotype acute leukaemia 68
Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia 67
Leukemia blast cell identification 66
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 66
Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000 66
Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B cell precursor acute lymphoblastic leukemia 64
Symmetrical thalamic calcifications in a monozygotic twin: case report and literature review 64
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 63
The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL 63
Symmetrical thalamic calcifications in a monozygotic twin: case report and literature review 60
Spinal cord injury without radiographic abnormalities 60
Donor multipotent mesencymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. 59
Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia 57
Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death 56
Advanced Pediatric Myelodysplastic Syndromes. Can Immunophenotypic Characterization of Blasts Cells be a Diagnostic and Prognostic Tool? 53
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: Revisited in AIEOP-BFM protocol 53
Low-Blood Lymphocyte Number and Lymphocyte Decline as Key Factors in COPD Outcomes: A Longitudinal Cohort Study 51
FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia 50
Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies 50
Aspergillus flavus Disseminated Infection in Paediatric Acute Lymphoblastic Leukaemia: A Case Report 47
Flow cytometry application in hematological malignancies of childhood 46
La sindrome di Dandy Walker: follow-up in due differenti casistiche 45
Unrelated donor vs HLA-haploidentical a/b T-cell– and B-cell–depleted HSCT in children with acute leukemia 40
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration 40
MLL partner genes specify distinct biological and clinical signatures in pediatric acute myeloidleukemia. An AIEOP study. 39
Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP) 38
Time point-dependent concordance of flow cytometry and RQ-PCR inminimal residual disease detection in childhood acute lymphoblasticleukemia. 37
Identification Of Low Risk Group In Infants With Acute Lymphoblastic Leukemia By Flow Cytometric Minimal Residual Disease Measurement At Day 15 Of Interfant-99 and Interfant-06 Protocols Treatment 36
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 34
Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia 34
New methodologic approaches for immunophenotyping acute leukemias 33
Comparison of MRD detection by RQ-PCR and droplet digital PCRin pediatric Acute Lymphoblastic Leukemia before Hematopoietic Stem Cell Transplantation 33
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease 33
CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript 33
Acute Lymphoid Leukaemias (ALL) and Minimal Residual Disease in ALL 28
Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience 28
An extensive quality control and quality assurance (QC/QA) program significantly improves inter-laboratory concordance rates of flow-cytometric minimal residual disease assessment in acute lymphoblastic leukemia: An I-BFM-FLOW-network report 25
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 24
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 23
mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells 22
SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia 18
New methodologic approaches for immunophenotyping acute leukemias 16
Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia 15
Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system 10
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 8
NUP214-ABL1 fusion in childhood T-ALL 4
Totale 4884
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9365
article - articoli 8897
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 65
Totale 18327
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201833 0000 00 00 21273
2018/2019440 31241 42 525 1187157120
2019/20201048 11938756 115103 110131 1321158240
2020/2021976 434826185 5955 2175 113123103125
2021/20221074 467814059 4450 87122 8338130197
2022/2023757 149892590 13598 1165 95000
Totale 4884